US › Healthcare

Cardiff Oncology Inc (CRDF)

US · Healthcare · Biotechnology

$0.90-7.22%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$104,000

Revenue YoY

-14.0%

Net profit

$-9.2M

EPS

$-0.14

EPS estimate

$-0.17

Net margin

-8,876.9%

EPS came in at -0.14 against a street estimate of -0.17 — a beat of 17.6%.

Key statistics

Market cap

$78.6M

Forward P/E

0.0

P/B

3.90

Book value

$0.39

EPS (TTM)

$-0.60

52-week high

$3.31

52-week low

$0.76

50-day MA

$1.09

200-day MA

$1.58

Beta

1.42

Analyst view

Analysts rate Cardiff Oncology Inc a buy (3 buy, 3 hold, 0 sell out of 6) with an average price target of $5.81.

Shareholding

Insiders

6.20%

Institutions

22.12%

Largest institutional holders

Fund	Stake
LAURION CAPITAL MANAGEMENT LP	3.98%
Vanguard Capital Management, LLC	3.72%
Pfizer Inc	3.10%
Franklin Templeton Inc	1.55%
BlackRock Inc	1.25%
Blair William & Co	1.17%
Geode Capital Management, LLC	1.05%
UBS Group AG	0.82%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cardiff Oncology Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.